Yingying Zhu

1 article listing Yingying Zhu in Nature Communications, indexed by Paperzzz from Crossref and OSF.

1. Double-dose firmonertinib as first-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer harboring EGFR L858R mutation: a prospective, multicenter, phase II study (FIRM) Nature Communications